Ghiath Mikdadi, MD
Cardiovascular Disease · Hammond, LANPI 1881696078
Payments from drug & device makers
Across 1,664 payments — averaging $3396.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1.8M
- American Regent$1.2M
- Novartis$1.1M
- Bayer$384K
- AstraZeneca$257K
- Boehringer Ingelheim International GmbH$256K
- plus $690K from 52 others
Across 13 payments — averaging $200.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$1K
- Eli Lilly$1K
What the payments were for
- Consulting fees$3,2064%
- Speaking & faculty fees$44,42058%
- Travel & lodging$7,44310%
- Food & beverage$21,23928%
- Education$1670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$35,078
- ENTRESTO$8,288
- FUROSCIX$4,317
- EMBLEM$1,871
- CARDIOMEMS$1,297
- LEQVIO$1,188
- TurboHawk$1,125
- AVEIR$858
- FLOWTRIEVER CATHETER, S$311
- CT THROMBECTOMY SYSTEM KIT$311
- HawkOne$295
- Repatha$247
- VERQUVO$230
- Confirm Rx$178
- Kerendia$150
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$132
- COREVALVE EVOLUT R$126
- CardioMEMS HF System$125
- Edwards SAPIEN 3 Transcatheter Heart Valve$125
- XARELTO$107
How this compares
$5,652,419 in reported general payments places this provider in the 95th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 757 | $584,847 |
| EntrestoSacubitril/Valsartan | 587 | $476,422 |
| XareltoRivaroxaban | 427 | $297,665 |
| Repatha SureclickEvolocumab | 404 | $266,525 |
| FarxigaDapagliflozin Propanediol | 277 | $177,946 |
| JardianceEmpagliflozin | 151 | $129,146 |
| VascepaIcosapent Ethyl | 226 | $108,610 |
| BrilintaTicagrelor | 106 | $58,841 |
| FuroscixFurosemide | 12 | $44,524 |
| MultaqDronedarone Hcl | 36 | $43,975 |
| NexlizetBempedoic Acid/Ezetimibe | 79 | $42,413 |
| Ranolazine ErRanolazine | 219 | $12,638 |
| Metoprolol Succinate | 1,170 | $11,960 |
| OzempicSemaglutide | 13 | $11,839 |
| Praluent PenAlirocumab | 22 | $11,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $869 | $584,847757 claims |
| NovartisEntresto | $1,103,977 | $476,422587 claims |
| Johnson & JohnsonXarelto | $969 | $297,665427 claims |
| AstraZenecaFarxiga, Brilinta | $257,493 | $236,787383 claims |
| Boehringer IngelheimJardiance | $1,794,480 | $129,146151 claims |
| Scpharmaceuticals Inc.Furoscix | $4,508 | $44,52412 claims |
| Sanofi-aventis U.S. LLCMultaq | $228 | $43,97536 claims |
| Esperion Therapeutics, Inc.Nexlizet | $325 | $42,41379 claims |
| Novo NordiskOzempic | $185 | $11,83913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Hammond
- Georges KhoueiryHammond$16K
- Marc BernsteinSlidell$2.1M
- Anil ChhabraShreveport$1.9M
- Dale PresserCovington$1.7M
- William EavesShreveport$1.6M
- Assad MouhaffelWest Monroe$1.4M
- Wenwu ZhangShreveport$1.1M
- William SmithRuston$694K
- Imran ChaudryMonroe$371K
- Keith FerdinandNew Orleans$335K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.